恩瑞特药业阿尔茨海默病新药获批上市；热景生物拟斥1亿元~2亿元回购股份

Group 1 - Hejian Bio plans to repurchase shares worth 100 million to 200 million yuan, using its own funds, with a maximum price of 244 yuan per share, aiming to buy back 409,837 to 819,672 shares, which represents 0.44% to 0.88% of the total share capital [1] - The repurchase is intended for employee stock ownership plans or equity incentives, reflecting the company's confidence in its development [1] - The repurchase period is set for 12 months from the date of board approval, which is expected to stabilize the stock price and bind core talent for future R&D and market expansion [1] Group 2 - Enrite Pharmaceuticals has received approval from the National Medical Products Administration of China for its new drug, Memantine Hydrochloride Orally Disintegrating Tablets, aimed at treating moderate to severe Alzheimer's disease [2] - Memantine is a novel NMDA receptor antagonist that protects nerve cells and promotes cognitive function recovery, filling a gap in the domestic market for this dosage form [2] - The original drug was developed by Lundbeck in Denmark and was first approved in Europe in May 2002, with its domestic approval occurring in July 2012 [2] Group 3 - Novartis has announced that its drug, Remibrutinib Tablets, has been approved by the FDA for the treatment of adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic after H1 antihistamine treatment [3] - This product is the first BTK inhibitor approved by the FDA for CSU treatment, providing a new option by targeting and blocking the BTK signaling pathway to inhibit the release of histamine and other pro-inflammatory mediators from mast cells [3] - Remibrutinib is administered as an oral tablet taken twice daily, eliminating the need for injections and laboratory monitoring [3]